Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Florence Ader, Nathan Peiffer‐Smadja, Julien Poissy, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 12, pp. 1826-1837
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 2, pp. 209-221
Open Access | Times Cited: 297
ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection
Rajendra Karki, SangJoon Lee, Raghvendra Mall, et al.
Science Immunology (2022) Vol. 7, Iss. 74
Open Access | Times Cited: 169
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
Charan Thej Reddy Vegivinti, Kirk W. Evanson, Hannah Lyons, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 93
Microbiota regulation of viral infections through interferon signaling
Nurul I. Wirusanti, Megan T. Baldridge, Vanessa Harris
Trends in Microbiology (2022) Vol. 30, Iss. 8, pp. 778-792
Open Access | Times Cited: 69
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial
André C. Kalil, Aneesh K. Mehta, Thomas F. Patterson, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1365-1376
Open Access | Times Cited: 99
HIV and COVID-19: review of clinical course and outcomes
Lauren K. Barbera, Kevin Kamis, Sarah E. Rowan, et al.
HIV Research & Clinical Practice (2021) Vol. 22, Iss. 4, pp. 102-118
Open Access | Times Cited: 63
Interferon induction, evasion, and paradoxical roles during SARS‐CoV‐2 infection*
Carolina Chiale, Trever T. Greene, Elina I. Zúñiga
Immunological Reviews (2022) Vol. 309, Iss. 1, pp. 12-24
Open Access | Times Cited: 46
Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia
Helen C. Su, Huie Jing, Yu Zhang, et al.
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 561-585
Open Access | Times Cited: 31
Antiviral Therapy of COVID-19
Georgii Gudima, И.А. Кофиади, I.P. Shilovskiy, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8867-8867
Open Access | Times Cited: 24
Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review
Paula Andrea Cuartas Velásquez, Juan C. Hernández, Elkin Galeano, et al.
Clinical Pharmacology Advances and Applications (2024) Vol. Volume 16, pp. 1-25
Open Access | Times Cited: 10
After the Hurricane: Anti-COVID-19 Drugs Development, Molecular Mechanisms of Action and Future Perspectives
Hazim O. Khalifa, Yousef Al Ramahi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 739-739
Open Access | Times Cited: 10
Type I Interferons in COVID-19 Pathogenesis
Enrico Palermo, Daniele Di Carlo, Marco Sgarbanti, et al.
Biology (2021) Vol. 10, Iss. 9, pp. 829-829
Open Access | Times Cited: 43
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
Elisa Souza Vaz, Sandra V. Vassiliades, Jeanine Giarolla, et al.
European Journal of Clinical Pharmacology (2023) Vol. 79, Iss. 6, pp. 723-751
Open Access | Times Cited: 16
Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
Seungeun Ryoo, Dae-Hyup Koh, Su‐Yeon Yu, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0272826-e0272826
Open Access | Times Cited: 15
Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Chenyang Zhang, Huaqing Jin, Yi Feng Wen, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 38
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
Alessia Alunno, Aurélie Najm, Pedro Machado, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 1, pp. 34-40
Open Access | Times Cited: 37
The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations
Herman Goossens, Lennie Derde, Peter Horby, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 5, pp. e153-e158
Open Access | Times Cited: 34
Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease
Robert W. Cross, Zachary A. Bornholdt, Abhishek N. Prasad, et al.
JCI Insight (2022) Vol. 7, Iss. 10
Open Access | Times Cited: 26
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
David M. Lowe, Li‐An K. Brown, Kashfia Chowdhury, et al.
PLoS Medicine (2022) Vol. 19, Iss. 10, pp. e1004120-e1004120
Open Access | Times Cited: 26
Plasmacytoid dendritic cells during COVID-19: Ally or adversary?
Renée M. van der Sluis, Christian K. Holm, Martin R. Jakobsen
Cell Reports (2022) Vol. 40, Iss. 4, pp. 111148-111148
Open Access | Times Cited: 25
Antiviral Potential of Plants against COVID-19 during Outbreaks—An Update
Qazi Mohammad Sajid Jamal
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13564-13564
Open Access | Times Cited: 22
Immunovirological and environmental screening reveals actionable risk factors for fatal COVID-19 during post-vaccination nursing home outbreaks
Lize Cuypers, Els Keyaerts, Samuel L. Hong, et al.
Nature Aging (2023) Vol. 3, Iss. 6, pp. 722-733
Open Access | Times Cited: 13
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials
Nathália Mariana Santos Sansone, Matheus Negri Boschiero, Fernando Augusto Lima Marson
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2206-2206
Open Access | Times Cited: 4
Methodology and design of platform trials: a meta-epidemiological study
Tyler Pitre, Samantha Cheng, Ellen Cusano, et al.
Journal of Clinical Epidemiology (2023) Vol. 157, pp. 1-12
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top